Antiangiogenic effect of licochalcone A

Biochemical Pharmacology

Volumn 80, Issue 8, 2010, Pages 1152-1159

  Kim, Yoon Hee ^a   Shin, Eun Kyung ^a   Kim, Dae Hwan ^a   Lee, Hee Hwan ^a   Park, Jung Han Yoon ^a   Kim, Jin Kyung ^a  

^a Hallym University   (South Korea)

Author keywords

Angiogenesis; Human umbilical vascular endothelial cells; Licochalcone A; Vascular endothelial growth factor receptor

Indexed keywords

CD31 ANTIGEN; GROWTH FACTOR; KI 67 ANTIGEN; LICOCHALCONE A; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; CHALCONE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; TUMOR GROWTH; VASCULAR RING; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; GLYCYRRHIZA; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; AORTA; CHALCONES; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; GLYCYRRHIZA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77956231081     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.006     Document Type: Article

References (43)

1. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
3. Fayette J., Soria J.C., Armand J.P. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005, 41:1109-1116.
4. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
5. Gaballah K., Oakley R., Hills A., Ryan A., Partridge M. The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. Br J Cancer 2009, 101:418-423.
6. Duran I., Hotté S.J., Hirte H., Chen E.X., MacLean M., Turner S., et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007, 13:4849-4857.
7. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605.
8. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
9. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343.
10. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999, 4:915-924.
11. Cohen E.E., Davis D.W., Karrison T.G., Seiwert T.Y., Wong S.J., Nattam S., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10:247-257.
12. Little J.W. Complementary and alternative medicine: impact on dentistry. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 98:137-145.
13. Shibata S. Anti-tumorigenic chalcones. Stem Cells 1994, 12:44-52.
14. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 2002, 20:2653-2658.
15. Zhai L., Blom J., Chen M., Christensen S.B., Kharazmi A. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother 1995, 39:2742-2748.
16. Chen M., Christensen S.B., Blom J., Lemmich E., Nadelmann L., Fich K., et al. Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother 1993, 37:2550-2556.
17. Kwon H.S., Park J.H., Kim D.H., Kim Y.H., Park J.H., Shin H.K., et al. Licochalcone A isolated from licorice suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice. J Mol Med 2008, 86:1287-1295.
18. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008, 99:1501-1506.
19. Yi T., Yi Z., Cho S.G., Luo J., Pandey M.K., Aggarwal B.B., et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008, 68:1843-1850.
20. Basu P., Ghosh R.N., Grove L.E., Klei L., Barchowsky A. Angiogenic potential of 3-nitro-4-hydroxy benzene arsonic acid (roxarsone). Environ Health Perspect 2008, 116:520-523.
21. Vailhé B., Vittet D., Feige J.J. In vitro models of vasculogenesis and angiogenesis. Lab Investig 2001, 81:439-452.
22. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
23. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
24. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
25. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963-969.
26. Kim J.K., Shin E.K., Park J.H., Kim Y.H., Park J.H. Antitumor and antimetastatic effects of licochalcone A in mouse models. J Mol Med 2010, 88:829-838.
27. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
28. Quesada A.R., Muñoz-Chápuli R., Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006, 26:483-530.
29. Miller K.D., Sweeney C.J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195-1206.
30. Huang S.P., Wu M.S., Shun C.T., Wang H.P., Lin M.T., Kuo M.L., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004, 11:517-527.
31. Li A., Varney M.L., Valasek J., Godfrey M., Dave B.J., Singh R.K. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 2005, 8:63-71.
32. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
33. Nadelmann L., Tjørnelund J., Christensen E., Hansen S.H. High-performance liquid chromatographic determination of licochalcone A and its metabolites in biological fluids. J Chromatogr B Biomed Sci Appl 1997, 695:389-400.
34. Fu Y., Hsieh T.C., Guo J., Kunicki J., Lee M.Y., Darzynkiewicz Z., et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 2004, 322:263-270.
35. Park J.H., Lim H.J., Lee K.S., Lee S., Kwak H.J., Cha J.H., et al. Anti-proliferative effect of licochalcone A on vascular smooth muscle cells. Biol Pharm Bull 2008, 31:1996-2000.
36. Funakoshi-Tago M., Tanabe S., Tago K., Itoh H., Mashino T., Sonoda Y., et al. Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation. Mol Pharmacol 2009, 76:745-753.
37. Klein S., de Fougerolles A.R., Blaikie P., Khan L., Pepe A., Green C.D., et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002, 16:5912-5922.
38. Shono T., Ono M., Izumi H., Jimi S.I., Matsushima K., Okamoto T., et al. Involvement of the transcription factor NF-kappa B in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996, 8:4231-4239.
39. Mohan R., Hammers H., Bargagna-Mohan P., Zhan X., Herbstritt C., Ruiz A., et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7:115-122.
40. Tang F.Y., Nguyen N., Meydani M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 2003, 106:871-878.
41. Syed D.N., Afaq F., Kweon M.H., Hadi N., Bhatia N., Spiegelman V.S., et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 2007, 26:673-682.
42. Kimura Y., Sumiyoshi M., Baba K. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci 2008, 99:2083-2096.
43. Jung M.H., Lee S.H., Ahn E.M., Lee Y.M. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009, 30:655-661.